Literature DB >> 9102232

[Hepatitis C].

A Gattoni1, A Cecere, R Caiazzo, C Romano.   

Abstract

HCV carriers are supposed to me 100,000,000 worldwide. 5-15% of subjects are infected via haemotransfusion and another significant amount via intravenous drugs; nevertheless in the major part of subjects the via of transmission remains unclear. HCV causes long-term infectious in the host because of its high frequency of mutations. Mutations origin multiple mutants, called quasi-species, who have distinct immunological features and can so easily escape host immune response. Chronic HCV infection leads to cirrhosis in 5-10 years and to a possible hepatocarcinoma in 15-20 years. Nevertheless, it remains unclear why some patients undergo a slight clinical course, while others experience an aggressive one (exitus in less than 5 years). Alpha-interferon (alpha-IFN) is at date the only drug of proven efficacy in HCV chronic hepatitis, even if HCV eradication is a rare event. The goal to obtain is to standardize doses and duration of the treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9102232

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  1 in total

Review 1.  Is interferon-beta an alternative treatment for chronic hepatitis C?

Authors:  Ricardo Moreno-Otero; María Trapero-Marugán; Elena Gómez-Domínguez; Luisa García-Buey; José A Moreno-Monteagudo
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.